ArticleCureus2025
Out of the Blue: Cyanosis and Methemoglobinemia in a Renal Transplant Patient Following Phenazopyridine Ingestion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Red Blood Cells Meet Carbon Monoxide: Yin and Yang in Medicines and Pharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methemoglobinemia is a rare but serious condition affecting the blood's ability to carry oxygen. Symptoms at presentation are often nonspecific. We describe the case of a 58-year-old female presenting with unexplained central cyanosis and severe hypoxia despite preserved respiratory effort and seemingly reassuring lab values. Further questioning revealed recent ingestion of a large quantity of phenazopyridine, an over-the-counter urinary analgesic known to cause oxidative stress. Co-oximetry confirmed significant elevation of methemoglobin levels. Methylene blue is well-regarded as the gold standard, and its use in treatment of this patient led to favorable clinical and laboratory improvement. Clinicians must maintain a high index of suspicion for dyshemoglobinemias in patients with unexplained cyanosis refractory to oxygen therapy, particularly when conventional metrics of oxygenation are inconsistent with the overall clinical picture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.